Amgen's Pediatric Psoriasis Study Yields Safety Data on Apremilast

Amgen's pediatric psoriasis study has reached completion, offering investors valuable insights into the long-term safety of apremilast in children and teenagers. The Phase 3 trial focused on mild to moderate plaque psoriasis in patients aged 6 to 17, confirming that apremilast is safe for use in this age group.

The study aimed to show that the existing oral drug can be used more confidently in younger patients who lack convenient oral options. The treatment under review was apremilast, an oral pill already sold as Otezla, which children received at weight-based doses twice a day with no food limits.

The trial design was open-label and single-arm, meaning every child received apremilast instead of random assignment to a placebo. The core purpose was treatment safety, making the design simple but useful for real-world prescribing decisions.